Pozitivf

About Pozitivf

Pozitivf Fertility, a San Antonio-based clinic network, is strategically positioned to disrupt the high-cost fertility treatment market by enhancing accessibility to care. Founded in 2022 by Dr. Francisco "Paco" Arredondo and Dr. Tony Anderson, the company operates on the core belief that having a family is a fundamental human right. This philosophy directly addresses a market where in vitro fertilization (IVF) can cost between $15,000 and $30,000 per cycle, a prohibitive expense for a large segment of the population.

The company's business model is centered on operational efficiency, inspired by lean management principles. By standardizing protocols, focusing on high-volume procedures, and eliminating non-essential add-ons, Pozitivf has significantly reduced overhead. This allows them to offer IVF services starting at approximately $7,995, nearly half the traditional cost, without compromising safety or quality. Their revenue is generated directly from these self-pay clinical services, with transparent pricing publicly available on their website—a departure from the typically opaque pricing structures in the fertility industry. This approach targets a demographic previously excluded from fertility treatments due to financial barriers.

The founders bring a substantial depth of experience to the venture. Dr. Arredondo, a Harvard-trained fertility specialist, has a long entrepreneurial history, including founding and selling a previous network of fertility centers. His journey began as part of the team that performed the first IVF in Mexico in 1989 and includes providing care to underserved populations in rural Kentucky. Co-founder Dr. Tony Anderson contributes over two decades of experience, having performed more than 10,000 IVF cycles and specialized in designing high-quality embryology labs. Their combined expertise underpins the clinic's ability to streamline the complex IVF process. This includes requiring initial diagnostic tests before the first visit to ensure every patient receives a clear treatment plan from the outset.

Pozitivf's primary service is IVF, a procedure involving egg extraction, laboratory fertilization, and embryo transfer. They also provide fertility evaluations, including anti-Müllerian hormone (AMH) blood tests, semen analysis, and HyFoSy for checking fallopian tubes. The company's streamlined process has shown promising results, reporting a 54% ongoing pregnancy rate from 245 procedures in one period, significantly higher than the CDC's reported national average success rate of 23.5% for all assisted reproductive technology cycles in 2021. Bolstered by a $20 million funding round led by MonCap, Pozitivf is expanding its footprint, with plans to open new clinics and further its mission of making fertility care a more attainable option for a broader demographic.